Science News
from research organizations

Turning Anthrax Toxin Into A Cancer Killer

Date:
January 5, 2008
Source:
American Society for Biochemistry and Molecular Biology
Summary:
Most people wouldn't consider anthrax toxin to be beneficial, but this bacterial poison may someday be an effective cancer therapy. Anthrax toxin has actually been shown to be fairly selective in targeting melanoma cells, although the risk of non-cancer toxicity prevents any clinical use.
Share:
       
Total shares:  
FULL STORY

After binding to cell surface markers, the MMP-activated PA protein (PA-L1) is cleaved by surface associated MMPs, releasing the PA20 fragment. The remaining receptor-bound fragment rapidly oligomerizes to form a heptamer. Up to three molecules of anthrax lethal factor (LF) bind to the heptamer, which is then internalized. Once inside the cell, the complex encounters an acidic environment, which induces a conformational change and allows the LF to enter the cytosol. LF released into the cytosol shuts down multiple signaling pathways, leading to inhibition of tumor angiogenesis and human melanoma cell death.
Credit: Image created by Drs. Shihui Liu, Mahtab Moayeri, and Stephen H. Leppla

Most people wouldn't consider anthrax toxin to be beneficial, but this bacterial poison may someday be an effective cancer therapy. Anthrax toxin has actually been shown to be fairly selective in targeting melanoma cells, although the risk of non-cancer toxicity prevents any clinical use.

To develop a better and safer treatment, Stephen Leppla and colleagues created a mutated antrax toxin that could only be turned on by matrix metalloproteinases (MMP), proteins that are overproduced only in cancer cells.

When they tested this mutated toxin in mice, the researchers observed that 100% of the animals tolerated a dose that would be lethal for the natural toxin. The MMP-toxin was also better at killing melanoma tumors than natural toxin, due to its higher specificity and longer half-life in the blood.

Even better, Leppla and colleagues saw that MMP-toxin was not limited to melanoma, and could also kill other tumors like colon and lung. This more widespread activity was due to the toxin's ability to inhibit angiogenesis, or the formation of new blood vessels.

These encouraging mouse results suggest that modified anthrax toxin could be clinically viable, and this potent killer might someday be put to good use.


Story Source:

The above story is based on materials provided by American Society for Biochemistry and Molecular Biology. Note: Materials may be edited for content and length.


Cite This Page:

American Society for Biochemistry and Molecular Biology. "Turning Anthrax Toxin Into A Cancer Killer." ScienceDaily. ScienceDaily, 5 January 2008. <www.sciencedaily.com/releases/2007/12/071231111915.htm>.
American Society for Biochemistry and Molecular Biology. (2008, January 5). Turning Anthrax Toxin Into A Cancer Killer. ScienceDaily. Retrieved May 23, 2015 from www.sciencedaily.com/releases/2007/12/071231111915.htm
American Society for Biochemistry and Molecular Biology. "Turning Anthrax Toxin Into A Cancer Killer." ScienceDaily. www.sciencedaily.com/releases/2007/12/071231111915.htm (accessed May 23, 2015).

Share This Page:


Health & Medicine News
May 23, 2015

Latest Headlines
updated 12:56 pm ET